content: <PAGE>  1
                   SECURITIES AND EXCHANGE COMMISSION
      
                        Washington, D.C.  20549
      
                             FORM 8-K
      
                           CURRENT REPORT
      
      
                   PURSUANT TO SECTION 13 OR 15(d) OF
                   THE SECURITIES EXCHANGE ACT OF 1934
      
      
      Date of Report (Date of earliest event reported)-September 11,1996
      
                 ADVANCED VIRAL RESEARCH CORP.            
         (Exact name of registrant as specified in its charter)
      
           Delaware                  33-2262-A         59-2646820       
      (State or other juris-     (Commission File     (IRS Employer
      diction of incorporation)      Number)          Identification No.)
      
                 1250 East Hallandale Beach Blvd.,  Suite 501
                 Hallandale, Florida                    33009   
         (Address or principal executive offices)     (Zip Code)
      
      
      Registrant's telephone number, including area code: (954)458-7636
      
      
                             None
      (Former name or former address, if changed since last report)
    
  <PAGE>  2
    
      Item 1.    Changes in Control of Registrant
      
            Not Applicable
      
      Item 2.    Acquisition or Disposition of Assets
      
            Not Applicable
      
      Item 3.    Bankruptcy or Receivership
      
            Not Applicable
     
      Item 4.    Changes in Registrant's Certifying Accountant
      
            Not Applicable
      
      Item 5.    Other Events
    
       On September 11, 1996, Advanced Viral Research Corp. (the
    "Company") received a written translation (the "Translation") of a
    report, in part authored by Dr. Juan Carlos Flichman, regarding
    certain results reported by Dr. Flichman in connection with a
    clinical trial assessing the efficacy of the Company's drug
    Reticulose on the Humanopapilloma Virus (the "Clinical Trial").  The
    Clinical Trial was conducted under Dr. Flichman's supervision in a
    hospital located in Buenos Aires, Argentina pursuant to a protocol
    developed by Dr. Flichman. 
    
       The Translation provides that 20 persons (6 males and 14
    females) diagnosed to be infected with HPV were treated topically
    with Reticulose.  The Translation concludes that based on the
    remissions and the clinical improvement observed in 50% of the
    patients, the Translation recommends and encourages that Reticulose
    be used as an alternative in biological treatment in Humanopapilloma
    Viruses. 
    
       A copy of the translation is provided as Exhibit 1 to this
    Current Report of Form 8-K.  
    
      Item 6. Resignations of Registrant's Directors
      
              Not Applicable
      
      Item 7. Financial Statements and Exhibits
      
            (a)  Financial statements of business acquired
      
                 None
      
            (b)  Pro forma financial information
      
                 None
      
            (c)  Exhibits
    
            (1)  Report, translated from Spanish to English,
    authored by Dr. Juan Carlos Flichman regarding certain results in
    connection with a clinical trial assessing the efficacy of the
    Company's drug Reticulose on the Humanpapilloma Virus.
    
    
      Item 8. Change in Fiscal Year
      
              Not Applicable
      
      <PAGE>  3
                             SIGNATURES
      
       Pursuant to the requirements of the Securities Exchange Act of
    1934, the registrant has duly caused this report to be signed on its
    behalf by the undersigned hereunto duly authorized.
      
      
                                ADVANCED VIRAL RESEARCH CORP.     
    
                                (Registrant)
      
      
      
      Dated: September 25, 1996       By: /s/ William Bregman      
                                          William Bregman
                                          Secretary-Treasurer
      
      
      
      
      <PAGE>  4
    
                        LIST OF EXHIBITS
      
    
            (1)  Report, translated from Spanish to English,
    authored by Dr. Juan Carlos Flichman regarding certain results in
    connection with a clinical trial assessing the efficacy of the
    Company's drug Reticulose on the Humanpapilloma Virus.
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 4137}]
metadata_filer: {"company-data": {"conformed-name": "ADVANCED VIRAL RESEARCH CORP", "cik": "0000786623", "assigned-sic": "2834", "irs-number": "592646820", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "033-02262-A", "film-number": "96634878"}, "business-address": {"street1": "1250 E HALLANDALE BEACH BLVD", "street2": "STE 501", "city": "HALLANDALE", "state": "FL", "zip": "33009", "phone": "9544587636"}}
text: 1
                   SECURITIES AND EXCHANGE COMMISSION
      
                        Washington, D.C.  20549
      
                             FORM 8-K
      
                           CURRENT REPORT
      
      
                   PURSUANT TO SECTION 13 OR 15(d) OF
                   THE SECURITIES EXCHANGE ACT OF 1934
      
      
      Date of Report (Date of earliest event reported)-September 11,1996
      
                 ADVANCED VIRAL RESEARCH CORP.            
         (Exact name of registrant as specified in its charter)
      
           Delaware                  33-2262-A         59-2646820       
      (State or other juris-     (Commission File     (IRS Employer
      diction of incorporation)      Number)          Identification No.)
      
                 1250 East Hallandale Beach Blvd.,  Suite 501
                 Hallandale, Florida                    33009   
         (Address or principal executive offices)     (Zip Code)
      
      
      Registrant's telephone number, including area code: (954)458-7636
      
      
                             None
      (Former name or former address, if changed since last report)
  2
    
      Item 1.    Changes in Control of Registrant
      
            Not Applicable
      
      Item 2.    Acquisition or Disposition of Assets
      
            Not Applicable
      
      Item 3.    Bankruptcy or Receivership
      
            Not Applicable
     
      Item 4.    Changes in Registrant's Certifying Accountant
      
            Not Applicable
      
      Item 5.    Other Events
    
       On September 11, 1996, Advanced Viral Research Corp. (the
    "Company") received a written translation (the "Translation") of a
    report, in part authored by Dr. Juan Carlos Flichman, regarding
    certain results reported by Dr. Flichman in connection with a
    clinical trial assessing the efficacy of the Company's drug
    Reticulose on the Humanopapilloma Virus (the "Clinical Trial").  The
    Clinical Trial was conducted under Dr. Flichman's supervision in a
    hospital located in Buenos Aires, Argentina pursuant to a protocol
    developed by Dr. Flichman. 
    
       The Translation provides that 20 persons (6 males and 14
    females) diagnosed to be infected with HPV were treated topically
    with Reticulose.  The Translation concludes that based on the
    remissions and the clinical improvement observed in 50% of the
    patients, the Translation recommends and encourages that Reticulose
    be used as an alternative in biological treatment in Humanopapilloma
    Viruses. 
    
       A copy of the translation is provided as Exhibit 1 to this
    Current Report of Form 8-K.  
    
      Item 6. Resignations of Registrant's Directors
      
              Not Applicable
      
      Item 7. Financial Statements and Exhibits
      
            (a)  Financial statements of business acquired
      
                 None
      
            (b)  Pro forma financial information
      
                 None
      
            (c)  Exhibits
    
            (1)  Report, translated from Spanish to English,
    authored by Dr. Juan Carlos Flichman regarding certain results in
    connection with a clinical trial assessing the efficacy of the
    Company's drug Reticulose on the Humanpapilloma Virus.
    
    
      Item 8. Change in Fiscal Year
      
              Not Applicable
  3
                             SIGNATURES
      
       Pursuant to the requirements of the Securities Exchange Act of
    1934, the registrant has duly caused this report to be signed on its
    behalf by the undersigned hereunto duly authorized.
      
      
                                ADVANCED VIRAL RESEARCH CORP.     
    
                                (Registrant)
      
      
      
      Dated: September 25, 1996       By: /s/ William Bregman      
                                          William Bregman
                                          Secretary-Treasurer
  4
    
                        LIST OF EXHIBITS
      
    
            (1)  Report, translated from Spanish to English,
    authored by Dr. Juan Carlos Flichman regarding certain results in
    connection with a clinical trial assessing the efficacy of the
    Company's drug Reticulose on the Humanpapilloma Virus.